Dewpoint Therapeutics: Funding, Investors & Team (Sep 2026)
Dewpoint Therapeutics is a biotech company developing a drug platform that targets biomolecular condensates. Its technology uses machine-learning-based image analysis tools for visualizing condensates and offers an engine for genetically linked condensatopathy which is a collection of engineered cell lines with trackable condensates to prevent harmful protein sequestration, helping healthcare providers to have access to new therapies to address unmet needs. The company was founded in 2018 and is headquartered in Boston, Massachusetts.
Dewpoint Therapeutics has raised $150M across 2 funding rounds on record, the most recent a Series D announced in Sep 2025.
Dewpoint Therapeutics Company Profile and Key Stats
Latest funding round on record: Sep 2025.
Dewpoint Therapeutics Funding Rounds
1 of 2 rounds was announced without a disclosed amount and is excluded from the total.
Dewpoint Therapeutics raised $150M in a Series C announced in Feb 2022.
3.6 years later, a Series D was announced in Sep 2025 with no disclosed amount.
Dewpoint Therapeutics Founders and Leadership Team
Contact details for the Dewpoint Therapeutics team: 1 of 2 have an email address on file, 1 has a LinkedIn profile.
Start 14-day free trial →Dewpoint Therapeutics Funding Compared to Other Biotechnology Startups
Funded Startups Like Dewpoint Therapeutics in Biotechnology and Boston
Companies Similar to Dewpoint Therapeutics
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Dewpoint Therapeutics Funding FAQs
What does Dewpoint Therapeutics do?
Dewpoint Therapeutics is a biotech company developing a drug platform that targets biomolecular condensates. Its technology uses machine-learning-based image analysis tools for visualizing condensates and offers an engine for genetically linked condensatopathy which is a collection of engineered cell lines with trackable condensates to prevent harmful protein sequestration, helping healthcare providers to have access to new therapies to address unmet needs. The company was founded in 2018 and is headquartered in Boston, Massachusetts.
How much funding has Dewpoint Therapeutics raised?
Dewpoint Therapeutics has raised $150M across 2 rounds on record.
When did Dewpoint Therapeutics last raise funding?
Dewpoint Therapeutics' most recent funding round on record was announced in Sep 2025. The amount was not disclosed.
Who is the CEO of Dewpoint Therapeutics?
Sandra Kleinstück is listed as CEO at Dewpoint Therapeutics.
Where is Dewpoint Therapeutics headquartered?
Dewpoint Therapeutics is based in Boston, Massachusetts, United States.
How many employees does Dewpoint Therapeutics have?
Dewpoint Therapeutics is in the 101-250 employee band.
About FundedIQ's Dewpoint Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Dewpoint Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.